To better discriminate the effect of IMID therapy on the ability to respond to Mtb stimulation, we stratified the patients according to the type of IMID therapy (Tables 2, 3) Immunosuppressive therapy in the TBI-IMID and TB-IMID cohorts did not have an impact on the number of Mtb responders evaluated as Th1 CD4+ T cells and CD25+CD134+ CD4+ T cells (AIM assay) (Tables 2, 3). The gene discussed is TNFRSF4; the disease is tuberculosis.